Marc Schmalzing
Overview
Explore the profile of Marc Schmalzing including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
98
Citations
1280
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Schwaneck E, Harasim A, Tony H, Gawlik M, Witte T, Joos S, et al.
Z Rheumatol
. 2024 Aug;
84(1):68-74.
PMID: 39174715
Background: Vaccinations represent an easily accessible, safe, and important method for preventing infections. Patients with primary immunodeficiencies (PID) are more susceptible to infections and should receive an extended spectrum of...
12.
Strunz P, Englbrecht M, Risser L, Witte T, Froehlich M, Schmalzing M, et al.
Rheumatol Int
. 2024 Aug;
44(10):2057-2066.
PMID: 39136784
In recent years Janus kinase inhibitors (JAKi) have joined tumor necrosis factor inhibitors (TNFi) and interleukin (IL)-17 inhibitors (IL-17i) as approved disease modifying anti-rheumatic drugs (DMARD) for moderate to severe...
13.
Labinsky H, Nagler L, Krusche M, Griewing S, Aries P, Kroiss A, et al.
Rheumatol Int
. 2024 Aug;
44(10):2043-2053.
PMID: 39126460
Background: The complex nature of rheumatic diseases poses considerable challenges for clinicians when developing individualized treatment plans. Large language models (LLMs) such as ChatGPT could enable treatment decision support. Objective:...
14.
Strunz P, Englbrecht M, Risser L, Witte T, Froehlich M, Schmalzing M, et al.
Front Immunol
. 2024 Jun;
15:1395968.
PMID: 38846940
Objective: Treatment options with disease-modifying antirheumatic drugs (DMARDs) for psoriatic arthritis (PsA) have evolved over recent years. In addition to Janus kinase inhibitors (JAKi), four classes of biologic DMARDs (bDMARDs;...
15.
Strunz P, Le Maire M, Heusinger T, Klein J, Labinsky H, Fleischer A, et al.
Rheumatol Int
. 2024 Apr;
44(6):1143-1154.
PMID: 38683351
Background: Patients with axial spondyloarthritis (axSpA) benefit from regular home-based exercise (HbE). In spite of recommendations, a relevant proportion of German axSpA patients does not adhere to recommended HbE practices....
16.
Froehlich M, Guggenberger K, Vogt M, Mihatsch P, Dalla Torre G, Werner R, et al.
Rheumatology (Oxford)
. 2024 Feb;
63(10):2781-2790.
PMID: 38305463
Objectives: Our aim was to introduce a standardized system for assessing the extent of GCA on MRI, i.e. the Magnetic Resonance Vasculitis Activity Score (MRVAS). To obtain a comprehensive view,...
17.
Rack C, Almanzar G, Schafer A, Volkl S, Dobler G, Mutterer A, et al.
Vaccine
. 2024 Jan;
42(4):745-752.
PMID: 38242736
Inactivated vaccines, such as tick-borne-encephalitis-virus-(TBEV) vaccine, have been discussed as less immunogenic in elderly and in immunocompromised patients. In this controlled cross-sectional cohort study, the antibody and cellular responses after...
18.
Guggenberger K, Vogt M, Song J, Frohlich M, Schmalzing M, Venhoff N, et al.
Rheumatology (Oxford)
. 2024 Jan;
64(2):842-848.
PMID: 38197587
Objective: Giant cell arteritis (GCA) is a large vessel vasculitis, typically involving the aorta and its branches with predilection for the scalp arteries. Intracranial involvement is still part of ongoing...
19.
Strunz P, Labinsky H, Nagler L, Portegys J, Froehlich M, Gernert M, et al.
Front Immunol
. 2023 Dec;
14:1294496.
PMID: 38045701
Autologous hematopoietic stem cell transplantation (aHSCT) represents an effective treatment option in patients with severe forms of systemic sclerosis (SSc) by resetting the immune system. Nevertheless, secondary autoimmune disorders and...
20.
Rubbert-Roth A, Kakehasi A, Takeuchi T, Schmalzing M, Palac H, Coombs D, et al.
Rheumatol Ther
. 2023 Nov;
11(1):97-112.
PMID: 37982966
Introduction: This article aims to describe malignancies in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), or non-radiographic axial spondyloarthritis (nr-axSpA) treated with upadacitinib (UPA) or active...